

## Press Cutting

| Citigate  
Dewe Rogerson

Publication: Investors Chronicle

Date: 10 October 2013

Hutchison China Meditech (HCM) has signed a licensing and co-development deal with Eli Lilly for its Fruquintinib oncology therapy which could be worth up to £86.5m in milestone payments before royalties kick in. The company also received a \$6m milestone payment from Janssen Pharmaceuticals for progress in an immunology product.